ACTG A5095 THREE PROTEASE INHIBITOR-SPARING REGIMENS IN HIV PATIENTS

ACTG A5095 HIV 患者的三种蛋白酶抑制剂保留方案

• 批准号: 7376984
• 负责人: JEFFERY L MEIER
• 金额: $ 0.13万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376984
• 关键词: ACTG; A5095; THREE; PROTEASE; INHIBITOR

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives of this study are: 1) To compare the ability of the three initial protease inhibitor-sparing antiretroviral regimens to suppress and maintain HIV-1 RNA <200 copies/mL. 2) To determine the safety and tolerability of the three initial protease inhibitor-sparing regimens.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的主要目的是：1）比较三种初始蛋白酶抑制剂保留抗逆转录病毒方案抑制和维持HIV-1 RNA <200拷贝/mL的能力。2)确定三种初始蛋白酶保留方案的安全性和耐受性。